1887
Volume 2015, Issue 1
  • ISSN: 2305-7823
  • E-ISSN:

Abstract

Early pharmacological interventions on transgenic models of hypertrophic cardiomyopathy (HCM) using angiotensin receptor blockers (ARBs) may be effective in preventing development of clinical phenotype or causing phenotype regression in early stages of disease. In the clinical setting, however, the effects of ARBs on HCM phenotype have been less consistent. INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan) was designed to assess the effect of 100 mg of losartan in promoting the regression of LV hypertrophy in HCM. The primary end-point of the study was the reduction in LV mass assessed by MRI or computed tomography. After 12 months, no reduction in LV mass was observed in the losartan arm, and there was no difference in LV mass change with the placebo arm. The same was true for all secondary endpoints. The implications of these findings are discussed in the light of further, ongoing study targeting the HCM phenotype.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2015.7
2015-03-01
2019-04-25
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2015/1/gcsp.2015.7.html?itemId=/content/journals/10.5339/gcsp.2015.7&mimeType=html&fmt=ahah

References

  1. [1]. Maron   BJ., , Ommen   SR., , Semsarian   C., , Spirito   P., , Olivotto   I., , Maron   MS. . Hypertrophic cardiomyopathy: Present and future, with translation into contemporary cardiovascular medicine. . J Am Coll Cardiol.   2014; ;64: : 83– 99 .
    [Google Scholar]
  2. [2]. Watkins   H., , Ashrafian   H., , Redwood   C. . Inherited cardiomyopathies. . N Engl J Med.   2011; ;364: : 1643– 1656 .
    [Google Scholar]
  3. [3]. van der Velden   J., , Ho   CY., , Tardiff   J., , Olivotto   I., , Knollmann   BC., , Carrier   L. . Research priorities in sarcomeric cardiomyopathies. . Cardiovasc Res.   2015 Jan 28; ; , pii: cvv019. [Epub ahead of print] .
    [Google Scholar]
  4. [4]. Spoladore   R., , Maron   MS., , D'Amato   R., , Camici   PG., , Olivotto   I. . Pharmacological treatment options for hypertrophic cardiomyopathy: High time for evidence. . Eur Heart J . 2012; ;33: : 1724– 1733 .
    [Google Scholar]
  5. [5]. Abozguia   K., , Elliott   P., , McKenna   W., , Phan   TT., , Nallur-Shivu   G., , Ahmed   I., , Maher   AR., , Kaur   K., , Taylor   J., , Henning   A., , Ashrafian   H., , Watkins   H., , Frenneaux   M. . Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. . Circulation . 2010; ;122: : 1562– 1569 .
    [Google Scholar]
  6. [6]. Ho   CY., , Lakdawala   NK., , Cirino   AL., , Lipshultz   SE., , Sparks   E., , Abbasi   SA., , Kwong   RY., , Antman   EM., , Semsarian   C., , González   A., , López   B., , Diez   J., , Orav   EJ., , Colan   SD., , Seidman   CE. . Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: A pilot randomized trial to modify disease expression. . JACC Heart Fail . 2014 Oct 31; ; , pii: S2213-1779(14)00445-4. doi: 10.1016/j.jchf.2014.08.003. [Epub ahead of print] .
    [Google Scholar]
  7. [7]. Axelsson   A., , Iversen   K., , Vejlstrup   N., , Ho   C., , Norsk   J., , Langhoff   L., , Ahtarovski   K., , Corell   P., , Havndrup   O., , Jensen   M., , Bundgaard   H. . Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: The INHERIT randomised, double-blind, placebo-controlled trial. . Lancet Diabetes Endocrinol . 2014; ; , published online Dec 19. DOI: http://dx.doi.org/10.1016/S2213-8587(14)70241-4 .
    [Google Scholar]
  8. [8]. Marian   AJ. . Experimental therapies in hypertrophic cardiomyopathy. . J Cardiovasc Transl Res.   2009; ;2: : 483– 492 .
    [Google Scholar]
  9. [9]. Teekakirikul   P., , Eminaga   S., , Toka   O., , Alcalai   R., , Wang   L., , Wakimoto   H., , Nayor   M., , Konno   T., , Gorham   JM., , Wolf   CM., , Kim   JB., , Schmitt   JP., , Molkentin   JD., , Norris   RA., , Tager   AM., , Hoffman   SR., , Markwald   RR., , Seidman   CE., , Seidman   JG. . Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. . J Clin Invest.   2010; ;120: : 3520– 3529 .
    [Google Scholar]
  10. [10]. Penicka   M., , Gregor   P., , Kerekes   R., , Marek   D., , Curila   K., , Krupicka   J. . The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: A pilot, randomized study. . J Mol Diagn . 2009; ;11: : 35– 41 .
    [Google Scholar]
  11. [11]. Yamazaki   T., , Suzuki   J., , Shimamoto   R., , Tsuji   T., , Ohmoto-Sekine   Y., , Ohtomo   K., , Nagai   R. . A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an angiotensin II receptor blocker. . Int Heart J . 2007; ;48: : 715– 724 .
    [Google Scholar]
  12. [12]. Araujo   AQ., , Arteaga   E., , Ianni   BM., , Buck   PC., , Rabello   R., , Mady   C. . Effect of losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. . Am J Cardiol . 2005; ;96: : 1563– 1567 .
    [Google Scholar]
  13. [13]. Shimada   YJ., , Passeri   JJ., , Baggish   AL., , O'Callaghan   C., , Lowry   PA., , Yannekis   G., , Abbara   S., , Ghoshhajra   BB., , Rothman   RD., , Ho   CY., , Januzzi   JL., , Seidman   CE., , Fifer   MA. . Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. . JACC Heart Fail . 2013; ;1: : 480– 487 .
    [Google Scholar]
  14. [14]. van Dockum   WG., , Beek   AM., , ten Cate   FJ., , ten Berg   JM., , Bondarenko   O., , Götte   MJ., , Twisk   JW., , Hofman   MB., , Visser   CA., , van Rossum   AC. . Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. . Circulation . 2005; ;111: : 2503– 2508 .
    [Google Scholar]
  15. [15]. El-Hamamsy   I., , Lekadir   K., , Olivotto   I., , El Guindy   A., , Merrifield   R., , Rega   L., , Yang   G., , Cecchi   F., , Yacoub   MH. . Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy. . Glob Cardiol Sci Pract.   2012 Jul 3; ;2012: 1 : 9 . doi:10.5339/gcsp.2012.9 .
    [Google Scholar]
  16. [16]. Todiere   G., , Aquaro   GD., , Piaggi   P., , Formisano   F., , Barison   A., , Masci   PG., , Strata   E., , Bacigalupo   L., , Marzilli   M., , Pingitore   A., , Lombardi   M. . Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. . J Am Coll Cardiol . 2012; ;60: : 922– 929 .
    [Google Scholar]
  17. [17]. Force   T., , Bonow   RO., , Houser   SR., , Solaro   RJ., , Hershberger   RE., , Adhikari   B., , Anderson   ME., , Boineau   R., , Byrne   BJ., , Cappola   TP., , Kalluri   R., , LeWinter   MM., , Maron   MS., , Molkentin   JD., , Ommen   SR., , Regnier   M., , Tang   WH., , Tian   R., , Konstam   MA., , Maron   BJ., , Seidman   CE. . Research priorities in hypertrophic cardiomyopathy: Report of a Working Group of the National Heart, Lung, and Blood Institute. . Circulation . 2010; ;122: : 1130– 1133 .
    [Google Scholar]
  18. [18]. Elliott   PM., , Anastasakis   A., , Borger   MA., , Borggrefe   M., , Cecchi   F., , Charron   P., , Hagege   AA., , Lafont   A., , Limongelli   G., , Mahrholdt   H., , McKenna   WJ., , Mogensen   J., , Nihoyannopoulos   P., , Nistri   S., , Pieper   PG., , Pieske   B., , Rapezzi   C., , Rutten   FH., , Tillmanns   C., , Watkins   H., , Authors/Task Force Members. . ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). . Eur Heart J.   2014; ;35: : 2733– 2779 .
    [Google Scholar]
  19. [19]. Schmieder   RE., , Martus   P., , Klingbeil   A. . Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. . JAMA . 1996; ;275: : 1507– 1513 .
    [Google Scholar]
  20. [20]. Olivotto   I., , Ommen   SR., , Maron   MS., , Cecchi   F., , Maron   BJ. . Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial?.   J Am Coll Cardiol.   2007; ;50: : 831– 834 .
    [Google Scholar]
  21. [21]. Jiang   J., , Wakimoto   H., , Seidman   JG., , Seidman   CE. . Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy. . Science.   2013; ;342: : 111– 114 .
    [Google Scholar]
  22. [22]. Gedicke-Hornung   C., , Behrens-Gawlik   V., , Reischmann   S., , Geertz   B., , Stimpel   D., , Weinberger   F., , Schlossarek   S., , Précigout   G., , Braren   I., , Eschenhagen   T., , Mearini   G., , Lorain   S., , Voit   T., , Dreyfus   PA., , Garcia   L., , Carrier   L. . Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice. . EMBO Mol Med.   2013 Jul; ;5: 7 : 1060– 1077 .
    [Google Scholar]
  23. [23]. Olivotto   I., , Tomberli   B., , Spoladore   R., , Mugelli   A., , Cecchi   F., , Camici   PG. . Hypertrophic cardiomyopathy: The need for randomized trials. . Glob Cardiol Sci Pract.   2013; ;2013: : 243– 248 , doi: 10.5339/gcsp.2013.31 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2015.7
Loading
  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error